Cefuroxime

Cefuroxime, sold under the brand name Zinacef among others, is an antibiotic used to treat and prevent a number of bacterial infections. These include pneumonia, meningitis, otitis media, sepsis, urinary tract infections, and Lyme disease. It is used by mouth or by injection into a vein or muscle.
Common side effects include nausea, diarrhea, allergic reactions, and pain at the site of injection. Serious side effects may include "Clostridium difficile" infection, anaphylaxis, and Stevens–Johnson syndrome. Use in pregnancy and breastfeeding is believed to be safe. It is a second-generation cephalosporin and works by interfering with a bacteria's ability to make a cell wall resulting in its death.
Cefuroxime was patented in 1971, and approved for medical use in 1977. It is on the World Health Organization's List of Essential Medicines. In 2017, it was the 342nd most commonly prescribed medication in the United States, with more than 800 thousand prescriptions.
Medical uses.
Cefuroxime is active against many bacteria including susceptible strains of Staphylococci and Streptococci, as well as a range of gram negative organisms. As with the other cephalosporins, it is susceptible to beta-lactamase, although as a second-generation variety, it is less so. Hence, it may have greater activity against "Haemophilus influenzae", "Neisseria gonorrhoeae", and Lyme disease. Unlike other second-generation cephalosporins, cefuroxime can cross the blood-brain barrier.
A systematic review found high quality evidence that injecting the eye with cefuroxime after cataract surgery will lower the chance of developing endophthalmitis after surgery.
Side effects.
Cefuroxime is generally well tolerated, and its side effects are usually transient. If ingested after food, this antibiotic is both better absorbed and less likely to cause its most common side effects of diarrhea, nausea, vomiting, headaches/migraines, dizziness, and abdominal pain compared to most antibiotics in its class.
Although a widely stated cross-allergic risk of about 10% exists between cephalosporins and penicillin, recent assessments have shown no increased risk for a cross-allergic reaction for cefuroxime and several other second-generation or later cephalosporins.
Chemistry.
Cefuroxime axetil is an acetoxyethyl ester prodrug of cefuroxime which is effective when taken by mouth. It is a second-generation cephalosporin.
Trade names.
In the U.S. it is marketed as "Zinacef" by Covis Pharmaceuticals since the company acquired the U.S. rights to the product from GSK. GSK had continued marketing a pediatric oral suspension as "Ceftin"; however, this presentation was discontinued as of 24 June 2017.
In Bangladesh, it is available as "Rofurox" by Radiant, "Kilbac" by Incepta and "Xorimax" by Sandoz. In India, it is available as "Ceftum" in tablet form and "Supacef" in injection form by GSK. In Poland, it is available as "Zamur" by Mepha, subsidiary of Teva Pharmaceutical Industries. In Australia, the "first generic" form of Cefuroxime axetil, "Pharmacor Cefuroxime" (tablets) from Pharmacor Pty Ltd, was registered on 27 March 2017, by the Therapeutic Goods Administration. Cefuroxime axetil is also available (in two strengths) as granules for oral suspension from Aspen Pharmacare Australia Pty Ltd under the brand name "Zinnat cefuroxime".